Gyre Therapeutics (NASDAQ:GYRE – Get Free Report) and Insmed (NASDAQ:INSM – Get Free Report) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, institutional ownership, dividends, risk, analyst recommendations, earnings and valuation.
Valuation & Earnings
This table compares Gyre Therapeutics and Insmed’s top-line revenue, earnings per share (EPS) and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Gyre Therapeutics | $113.45 million | 8.13 | -$92.93 million | N/A | N/A |
Insmed | $305.21 million | 34.96 | -$749.57 million | ($5.23) | -13.73 |
Gyre Therapeutics has higher earnings, but lower revenue than Insmed.
Profitability
Net Margins | Return on Equity | Return on Assets | |
Gyre Therapeutics | N/A | -730.65% | -124.94% |
Insmed | -236.74% | N/A | -56.78% |
Institutional & Insider Ownership
24.0% of Gyre Therapeutics shares are held by institutional investors. 2.9% of Gyre Therapeutics shares are held by company insiders. Comparatively, 4.6% of Insmed shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Analyst Recommendations
This is a summary of current ratings and price targets for Gyre Therapeutics and Insmed, as provided by MarketBeat.com.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Gyre Therapeutics | 0 | 0 | 0 | 0 | N/A |
Insmed | 0 | 0 | 16 | 0 | 3.00 |
Insmed has a consensus price target of $74.50, indicating a potential upside of 3.75%. Given Insmed’s higher possible upside, analysts clearly believe Insmed is more favorable than Gyre Therapeutics.
Volatility and Risk
Gyre Therapeutics has a beta of 2.12, suggesting that its share price is 112% more volatile than the S&P 500. Comparatively, Insmed has a beta of 1.16, suggesting that its share price is 16% more volatile than the S&P 500.
Summary
Insmed beats Gyre Therapeutics on 7 of the 11 factors compared between the two stocks.
About Gyre Therapeutics
Gyre Therapeutics, Inc., a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases. In addition, it advances a product pipeline in China, including Pirfenidone, for dermatomyositis interstitial lung disease, systemic sclerosis-associated interstitial lung disease, and pneumoconiosis, as well as for diabetic kidney disease; and product candidates for acute-on-chronic liver failure, chronic obstructive pulmonary disease, and pulmonary arterial hypertension. The company was founded in 2002 and is headquartered in San Diego, California.
About Insmed
Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed’s earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.
Receive News & Ratings for Gyre Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gyre Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.